Long-term survival in a young woman with recurrent HER2-positive breast cancer.
We report the case of a patient with HER2-positive breast cancer relapsing after 7 years from diagnosis with a HER2-positive tumor recurrence, treated with anti-HER2 drugs (pertuzumab, trastuzumab and lapatinib) associated to radiotherapy and/or chemotherapy. These therapeutic strategies allowed sat...
| Hlavní autor: | |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
AboutScience Srl
2018-06-01
|
| Edice: | AboutOpen |
| Témata: | |
| On-line přístup: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/53 |